Immunotherapy plus chemo shows promise for rare sinus cancer

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can shrink advanced sinonasal undifferentiated carcinoma (SNUC), a rare and aggressive sinus cancer. About 28 adults with newly diagnosed, locally advanced SNUC will receive the combination, then surgery, followed by more pembrolizumab. The goal is to improve tumor response and reduce side effects compared to chemotherapy alone.